Pharmaceutical giants like Lilly and Nordisk are battling for dominance in India’s weight-loss market with price cuts and ...

Hyderabad: Global pharma heavyweights Eli Lilly and Novo Nordisk are racing to lock in market leadership in India’s blooming ...

The race to treat obesity with powerful new medicines has become one of the defining stories in global healthcare, and Novo ...

The pharmaceutical giant's stock has tumbled over the past year and a half, but it could be poised to storm back.

The drugs' high prices, along with spotty insurance coverage, have left them out of reach for many Americans. Read more at ...

Novo Nordisk A/S secures FDA nod for oral Wegovy, expanding obesity treatment options. Click for how oral GLP-1 therapies ...

As Novo Nordisk’s weight-loss pill Wegovy (semaglutide) readies for a launch in the United States early January, it will be a ...

Pharmaceutical trafficking is becoming a public health problem, say medical authorities and patients ...

India's obesity drug market is experiencing rapid growth, driven by rising lifestyle diseases and the launch of blockbuster ...

U.S. regulators on Monday gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity. The U.S. Food and Drug Administration’s ...

Mint's pharma reporter Jessica Jani explores why India’s obsession with weight-loss shots is about more than just medicine.

BHVN’s investment case definitely weakened after Opakalim’s Phase 2 MDD miss. This also means they’ll discontinue their ...